Georgia's Online Cancer Information Center

Find A Clinical Trial

An Investigational Scan (18F-rhPSMA 7.3 PET/CT) with and without Furosemide for the Reduction of Bladder Activity in Patients with Biochemically Recurrent Prostate Cancer

Cancer Type
Prostate Cancer
Trial Phase
Phase II
18 Years and older, Male
Study Type
Protocol IDs
RAD5689-22-BED-IIT-439 (primary)
Study Sponsor
Emory University Hospital/Winship Cancer Institute


This phase II trial evaluates flotufolastat F-18 gallium radiohybrid prostate-specific membrane antigen (18F- rhPSMA)-7.3 positron emission tomography (PET)/computed tomography (CT) scans with and without furosemide for the reduction of bladder activity in patients with prostate cancer that has come back (recurrent) based on elevated levels of prostate-specific antigen (PSA) in the blood (biochemical) after prostate surgery (prostatectomy). Furosemide is a diuretic substance that increases the urine flow into the bladder, thereby decreasing the level of radioactivity within the bladder, which may help to see any abnormal areas that could be masked by the radioactivity within the bladder. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, rhPSMA ligand. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient’s body. Adding furosemide to 18F-rhPSMA 7.3 PET/CT scans may help to better detect and treat patients with biochemically recurrent prostate cancer.


I. To determine if administering 20 mg furosemide intravenously (IV) at the time of radiotracer injection significantly reduces bladder activity compared with the same patient scanned without furosemide as internal control.

I. To compare detection rates of recurrent disease in blinded interpretations between the furosemide and non-furosemide 18FrhPSMA-7.3 PET/CT scans, with patients serving as their own internal controls.
II. To compare reader confidence in identifying prostate bed and other recurrent lesions on a 18F-rhPSMA-7.3 PET/CT with furosemide compared with 18F-rhPSMA-7.3 PET/CT without furosemide.

Patients receive flotufolastat F-18 gallium tracer IV and then undergo PET-CT scans with and without furosemide IV 60-70 minutes post-injection.

Patients are followed up at 1-3 days after each PET/CT.


  1. Adenocarcinoma of the prostate, post-prostatectomy
  2. Biochemical recurrence of prostate cancer following radical prostatectomy (RP) with or without adjuvant or salvage therapy: PSA >= 0.1 ng/mL
  3. Age over 18
  4. Ability to provide written informed consent
  5. Patients with standard of care creatinine =< 1.3 mg/dL performed within 90 days prior to enrollment

Treatment Sites in Georgia

Emory Johns Creek Hospital

6325 Hospital Parkway
Johns Creek, GA 30097

Emory Saint Joseph's Hospital

5665 Peachtree Dunwoody Road NE
Atlanta, GA 30342

Emory University Hospital - Midtown

550 Peachtree Street NE
Atlanta, GA 30308

Winship Cancer Institute of Emory University

1365 Clifton Road NE
Building C
Atlanta, GA 30322

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.